BioCentury
ARTICLE | Clinical News

AAV2-hRPE65v2: Additional Phase I data

February 27, 2012 8:00 AM UTC

Researchers at the university and colleagues reported data from 3 patients who received AAV2-hRPE65v2 in 1 eye in an open-label Phase I trial showing that a second treatment with AAV2-hRPE65v2 in the contralateral eye given 1.7-3.3 years after their initial treatment was safe with no adverse events reported. Additionally, the patients were better able to see in dim light after the second treatment, and 2 patients were able to navigate obstacles in low-light situations. Furthermore, neither administration of AAV2-hRPE65v2 triggered an immune reaction that cancelled the benefits of the inserted genes. Data were published in Science Translational Medicine. ...